Recent advances in the epidemiology, assessment and management of refractory breathlessness in lung cancer — ASN Events

Recent advances in the epidemiology, assessment and management of refractory breathlessness in lung cancer (#84)

Irene Higginson 1
  1. King's College London, London, United Kingdom

Refractory breathlessness is defined as breathlessness at rest or on minimal exertion that persists despite optimal treatment of the underlying cause(s). Such breathlessness is a very common symptom in patients affected by lung cancer, at diagnosis, during treatment, in survivorship (after radiotherapy, chemotherapy or surgery) and in advanced cancer, occurring in between 60% of patients at diagnosis and 90% of those with advanced disease.

Patients and carers experience a high level of distress from this frightening symptom. It is a frequent cause of hospital admission. Recent research has show that breathlessness often follows a fluctuant course, even in cancer patients. In addition, episodic or crisis breathlessness can be especially difficult to control.

Breathlessness remains a difficult symptom to improve despite recent advances in cancer treatment. Its causes are multifactorial, and may relate to pathology in the lung, but also muscle weakness, especially of the legs with deconditioning, weight gain, anaemia or electrolyte disturbance. In patients with lung cancer underlying COPD may go undetected and treated, which becomes more problematic after cancer treatment. This presentation will review recent advances in pharmacological and non-pharmacological treatments, and new service developments to support patients with breathlessness, such as an integrated respiratory / palliative breathlessness support service.

  1. Currow DC, Abernethy AP, Ko DN The active identification and management of chronic refractory breathlessness is a human right Thorax doi:10.1136/thoraxjnl-2013-204701
  2. Reuben DB and Mor V Dyspnea in terminally ill cancer patients. Chest 1986; 89: 234-236
  3. Solano JP et al. A comparison of symptom prevalence in far advanced cancer, AIDs, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31: 58-69
  4. Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ. Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. Palliat Med. 2010 Dec;24(8):777-86. doi: 10.1177/0269216310378785. Epub 2010 Sep 16
  5. Weingärtner V, Bausewein C, Higginson IJ, Scheve C, Murtagh FE, Voltz R, Simon ST. Characterizing episodic breathlessness in patients with advanced disease. J Palliat Med. 2013 Oct;16(10):1275-9. doi: 10.1089/jpm.2013.0087. Epub 2013 Sep 20
#COSAASM